PTC Therapeutics holder plans $3.65M share sale
PTC THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PTC THERAPEUTICS, INC. (PTCT) received an amended Rule 144 notice indicating that Section Six Partners, L.P., identified as an affiliate of a director, plans to sell up to 50,000 shares of common stock through Merrill Lynch on NASDAQ. The amendment revises the seller’s name and related securities information. The shares to be sold were acquired on 06/25/2013 via automatic conversion of preferred stock into common stock upon the company’s IPO, from the issuer for cash. As of 08/19/2026, there were 83,460,802 shares of common stock outstanding. Director Michael Schmertzler, a general and limited partner of Section Six Partners, disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Key Figures
Key Terms
Rule 144 regulatory
automatic conversion financial
affiliate of Director regulatory
beneficial ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144/A filing for PTCT disclose?
AI-generated analysis. How Rhea-AI works. Not financial advice.